Investigational drug · Phase 3
I-DXd
Also called: DS-7300a, MK-2400, Ifinatamab deruxtecan
Not approved by FDA. In 17 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
17
17 still active
All registered trials
51
Any phase or sponsor naming "I-DXd"
First trial start
2019
Nov 3, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "I-DXd", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Esophageal Squamous Cell Carcinoma
- Extensive-stage Small-cell Lung Cancer
- Extensive Stage-small Cell Lung Cancer
- Oesophageal Squamous Cell Carcinoma
- Small Cell Lung Cancer Extensive Stage
- Advanced Solid Tumor
- Malignant Solid Tumor
- Small-Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "I-DXd" as an intervention, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06925737 · 1,440 participants (planned) · Start May 13, 2025 · Primary completion Jun 26, 2028
Drug: Ifinatamab deruxtecan; Docetaxel and 2 more · For: Prostate Cancer; Prostatic Neoplasms
Sites: Phoenix, Arizona; Clovis, California; Duarte, California · 303 sites in all
- A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05629585 · 1,174 participants · Start Nov 28, 2022 · Primary completion Sep 1, 2027
Drug: Dato-DXd; Durvalumab and 2 more · For: Breast Cancer
Sites: Gilbert, Arizona; Tucson, Arizona; Hot Springs, Arkansas · 276 sites in all
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07720284 · 915 participants (planned) · Start Jul 16, 2026 · Primary completion Sep 11, 2030
Drug: Dato-DXd; Rilvegostomig and 4 more · For: High-risk Muscle Invasive Urothelial Carcinoma
Sites: Hot Springs, Arkansas; Little Rock, Arkansas; San Francisco, California · 160 sites in all
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06324357 · 910 participants (planned) · Start Jun 28, 2024 · Primary completion Jan 8, 2029
Drug: Zongertinib; Trastuzumab deruxtecan and 6 more · For: Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma and 2 more
Sites: Cerritos, California; Los Angeles, California; Orange, California · 105 sites in all
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04644068 · 702 participants · Start Nov 12, 2020 · Primary completion May 28, 2027
Drug: AZD5305; Paclitaxel and 4 more · For: Ovarian Cancer; Breast Cancer; Pancreatic Cancer and 10 more
Sites: Boston, Massachusetts; New York, New York; Oklahoma City, Oklahoma · 68 sites in all
AstraZenecaAstraZeneca (AZN)
NCT05417594 · 695 participants (planned) · Start Jun 24, 2022 · Primary completion Feb 7, 2028
Drug: AZD9574; Temozolomide (TMZ) and 3 more · For: Advanced Solid Malignancies
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 32 sites in all
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06330064 · 680 participants (planned) · Start Apr 10, 2024 · Primary completion Jul 25, 2028
Drug: Ifinatamab deruxtecan · For: Recurrent or Metastatic Solid Tumors
Sites: Los Angeles, California; Whittier, California; Skokie, Illinois · 120 sites in all
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06203210 · 540 participants (planned) · Start May 21, 2024 · Primary completion Jan 30, 2028
Drug: Ifinatamab deruxtecan; Topotecan and 2 more · For: Small Cell Lung Cancer
Sites: Springdale, Arkansas; Fullerton, California; Los Angeles, California · 229 sites in all
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)Pivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06644781 · 510 participants (planned) · Start Mar 27, 2025 · Primary completion Jun 1, 2028
Drug: Ifinatamab deruxtecan; Docetaxel and 2 more · For: Esophageal Squamous Cell Carcinoma
Sites: Phoenix, Arizona; Fullerton, California; Los Angeles, California · 168 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical development of ABL206, a novel bispecific antibody-drug conjugate targeting B7-H3 and ROR1.
Kwon JA, Lee S, Kim J, et al. · MAbs 2026
- Antibodies to watch in 2026.
Crescioli S, Kaplon H, Chenoweth A, et al. · MAbs 2026
- B7-H3 molecular imaging for the era of pan-cancer targeted therapy.
Liu B, Wang K, He K, et al. · Front Pharmacol 2026
- Enhancing the efficacy of B7-H3-targeting antibody-drug conjugate DS-7300a in TP53-deficient tumors by inducing ferroptosis.
Leo J, Chen F, Shi W, et al. · Oncogene 2026
- Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan.
Wang J, Jiang H, Niu J, et al. · Front Immunol 2026
- B7-H3/CD276-specific nanobody T3CL11 enables tumor imaging in murine osteosarcoma and colorectal cancer models.
Chen WM, Kishore S, Ramanujam VS, et al. · Cell Rep 2026
Also in development for Small Cell Lung Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- ZG006Phase 38 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- ABBV-706Phase 34 trials
AbbVie · Small Cell Lung Cancer, Extensive Stage-Small Cell Lung Cancer (ES-SCLC), Extensive Stage-Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.